Home  /  Resource Library  /  Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Key points – Complex karyotype and fludarabine refractoriness are key risk factors for progression of CLL on venetoclax. Bruton tyrosine kinase inhibitors are active in patients with CLL after prior therapy with venetoclax.